Drug intelligence / Profile preview

HUC2-676-R

Development stage: Unknown
Lead developer: Huons
Modality: Peptides
Administration: Subcutaneous

Overview

HUC2-676-R is a synthetic peptide and a reformulation variant of HUC2-676, developed by Huons Co., Ltd. for the treatment of obesity. It functions as a glucagon-like peptide-1 receptor agonist (GLP-1RA), designed to be equivalent to liraglutide (Saxenda). The drug targets the GLP-1 receptor to promote insulin secretion, suppress glucagon secretion, and induce satiety through its action on the hypothalamus in the brain. It is currently being evaluated in Phase 1 clinical trials to compare its pharmacokinetics and safety profile with the original HUC2-676 formulation in healthy adult volunteers.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on HUC2-676-R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUC2-676-R.

Explore the full profile